Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 336

1.

Development and pilot evaluation of a personalized decision support intervention for low risk prostate cancer patients.

Belkora J, Chan JM, Cooperberg MR, Neuhaus J, Stupar L, Weinberg T, Broering JM, Tenggara I, Cowan JE, Rosenfeld S, Kenfield SA, Van Blarigan EL, Simko JP, Witte J, Carroll PR.

Cancer Med. 2019 Nov 12. doi: 10.1002/cam4.2685. [Epub ahead of print]

2.

African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study (PASS).

Schenk JM, Newcomb LF, Zheng Y, Faino AV, Zhu K, Nyame YA, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Filson CP, Gleave ME, Liss M, Martin FM, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW.

J Urol. 2019 Oct 25:101097JU0000000000000621. doi: 10.1097/JU.0000000000000621. [Epub ahead of print]

PMID:
31651227
3.

Prostate cancer mortality and metastasis under different biopsy frequencies in North American active surveillance cohorts.

Lange JM, Laviana AA, Penson DF, Lin DW, Bill-Axelson A, Carlsson SV, Newcomb LF, Trock BJ, Carter HB, Carroll PR, Cooperberg MR, Cowan JE, Klotz LH, Etzioni RB.

Cancer. 2019 Oct 22. doi: 10.1002/cncr.32557. [Epub ahead of print]

PMID:
31639200
4.

Reply by Authors.

Dambal S, Howard LE, Allott EH, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ.

J Urol. 2019 Oct 14:10109701JU000060407644320a0. doi: 10.1097/01.JU.0000604076.44320.a0. [Epub ahead of print] No abstract available.

PMID:
31609668
5.

Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer.

Higano CS, Armstrong AJ, Sartor AO, Vogelzang NJ, Kantoff PW, McLeod DG, Pieczonka CM, Penson DF, Shore ND, Vacirca J, Concepcion RS, Tutrone RF, Nordquist LT, Quinn DI, Kassabian V, Scholz MC, Harmon M, Tyler RC, Chang NN, Tang H, Cooperberg MR.

Cancer. 2019 Dec 1;125(23):4172-4180. doi: 10.1002/cncr.32445. Epub 2019 Sep 4.

PMID:
31483485
6.

Obesity at Diagnosis and Prostate Cancer Prognosis and Recurrence Risk Following Primary Treatment by Radical Prostatectomy.

Langlais CS, Cowan JE, Neuhaus J, Kenfield SA, Van Blarigan EL, Broering JM, Cooperberg MR, Carroll P, Chan JM.

Cancer Epidemiol Biomarkers Prev. 2019 Nov;28(11):1917-1925. doi: 10.1158/1055-9965.EPI-19-0488. Epub 2019 Aug 28.

PMID:
31462398
7.

Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance.

Herlemann A, Huang HC, Alam R, Tosoian JJ, Kim HL, Klein EA, Simko JP, Chan JM, Lane BR, Davis JW, Davicioni E, Feng FY, McCue P, Kim H, Den RB, Bismar TA, Carroll PR, Cooperberg MR.

Prostate Cancer Prostatic Dis. 2019 Aug 27. doi: 10.1038/s41391-019-0167-9. [Epub ahead of print]

PMID:
31455846
8.

Active surveillance for intermediate-risk prostate cancer: yes, but for whom?

Overland MR, Washington SL 3rd, Carroll PR, Cooperberg MR, Herlemann A.

Curr Opin Urol. 2019 Nov;29(6):605-611. doi: 10.1097/MOU.0000000000000671.

PMID:
31436567
9.

Serum Lipids Prior to Starting Androgen Deprivation Therapy and Risk of Castration Resistant Prostate Cancer and Metastasis: Results from the SEARCH Database.

Dambal S, Howard LE, Allott EH, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ.

J Urol. 2019 Aug 20:101097JU0000000000000494. doi: 10.1097/JU.0000000000000494. [Epub ahead of print]

PMID:
31430247
10.

Genomic Risk Predicts Molecular Imaging-detected Metastatic Nodal Disease in Prostate Cancer.

Xu MJ, Kornberg Z, Gadzinski AJ, Diao D, Cowan JE, Wu SY, Boreta L, Spratt DE, Behr SC, Nguyen HG, Cooperberg MR, Davicioni E, Roach M 3rd, Hope TA, Carroll PR, Feng FY.

Eur Urol Oncol. 2019 Nov;2(6):685-690. doi: 10.1016/j.euo.2018.11.002. Epub 2019 Jan 15.

PMID:
31411984
11.

Predictors of skeletal-related events and mortality in men with metastatic, castration-resistant prostate cancer: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.

Tablazon IL, Howard LE, De Hoedt AM, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ, Williams SB.

Cancer. 2019 Nov 15;125(22):4003-4010. doi: 10.1002/cncr.32414. Epub 2019 Aug 7.

PMID:
31390061
12.

Robust Health Utility Assessment Among Long-term Survivors of Prostate Cancer: Results from the Cancer of the Prostate Strategic Urologic Research Endeavor Registry.

Jeong CW, Cowan JE, Broering JM, Ten Ham RMT, Wilson LS, Carroll PR, Cooperberg MR.

Eur Urol. 2019 Dec;76(6):743-751. doi: 10.1016/j.eururo.2019.07.012. Epub 2019 Jul 23.

PMID:
31345635
13.

Automating the Capture of Structured Pathology Data for Prostate Cancer Clinical Care and Research.

Odisho AY, Bridge M, Webb M, Ameli N, Eapen RS, Stauf F, Cowan JE, Washington SL 3rd, Herlemann A, Carroll PR, Cooperberg MR.

JCO Clin Cancer Inform. 2019 Jul;3:1-8. doi: 10.1200/CCI.18.00084.

14.

Prostate cancer screening in low- and middle-income countries: the Mexican case.

Lajous M, Cooperberg MR, Rider J, Manzanilla-García HA, Gabilondo-Navarro FB, Rodríguez-Covarrubias FT, López-Ridaura R, Torres-Sánchez LE, Mohar A.

Salud Publica Mex. 2019 Jul-Ago;61(4):542-544. doi: 10.21149/10373. Epub 2019 Jul 16.

PMID:
31314214
15.

Practice patterns and outcomes of equivocal bone scans for patients with castration-resistant prostate cancer: Results from SEARCH.

Hanyok BT, Everist MM, Howard LE, De Hoedt AM, Aronson WJ, Cooperberg MR, Kane CJ, Amling CL, Terris MK, Freedland SJ.

Asian J Urol. 2019 Jul;6(3):242-248. doi: 10.1016/j.ajur.2019.01.004. Epub 2019 Jan 18.

16.

Salvage Radiotherapy for Recurrent Prostate Cancer: Can the Prognostic Grade Group System Inform Treatment Timing?

Tay KJ, Polascik TJ, Howard LE, Salama JK, Schulman AA, Chen Z, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ.

Clin Genitourin Cancer. 2019 Oct;17(5):e930-e938. doi: 10.1016/j.clgc.2019.05.007. Epub 2019 May 24.

PMID:
31257075
17.

Identification and Characterization of Circulating Tumor Cells in Men Who have Undergone Prostatectomy for Clinically Localized, High Risk Prostate Cancer.

Friedlander TW, Welty C, Anantharaman A, Schonhoft JD, Jendrisak A, Lee J, Li P, Hough J, Stromlund A, Edwards M, Sangar S, Kobayashi Y, Simko J, Farrokhian N, Lindquist K, Greene S, Ontiveros P, Graf R, Rodriquez A, Suraneni M, Wang Y, Landers M, Carroll P, Cooperberg MR, Dittamore R, Paris PL.

J Urol. 2019 Oct;202(4):732-741. doi: 10.1097/JU.0000000000000393. Epub 2019 Sep 6.

PMID:
31216253
18.

Interpretation of Domain Scores on the EPIC-How Does the Domain Score Translate into Functional Outcomes?

Laviana AA, Hernandez A, Huang LC, Zhao Z, Koyama T, Conwill R, Hoffman K, Feurer ID, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, O'Neil BB, Kaplan SH, Greenfield S, Penson DF, Barocas DA.

J Urol. 2019 Dec;202(6):1150-1158. doi: 10.1097/JU.0000000000000392. Epub 2019 Jun 19.

PMID:
31216252
19.

Effects of Initial Gleason Grade on Outcomes during Active Surveillance for Prostate Cancer.

Masic S, Cowan JE, Washington SL, Nguyen HG, Shinohara K, Cooperberg MR, Carroll PR.

Eur Urol Oncol. 2018 Oct;1(5):386-394. doi: 10.1016/j.euo.2018.04.018. Epub 2018 May 24.

PMID:
31158077
20.

Trends and Predictors of Adjuvant Therapy for Adverse Features Following Radical Prostatectomy: An Analysis From Cancer of the Prostate Strategic Urologic Research Endeavor.

Balakrishnan AS, Zhao S, Cowan JE, Broering JM, Cooperberg MR, Carroll PR.

Urology. 2019 Sep;131:157-165. doi: 10.1016/j.urology.2019.05.018. Epub 2019 May 28.

PMID:
31150694
21.

The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement.

Cooperberg MR, Carroll PR, Dall'Era MA, Davies BJ, Davis JW, Eggener SE, Feng FY, Lin DW, Morgan TM, Morgans AK, Spratt DE, Taneja SS, Penson DF.

Eur Urol. 2019 Sep;76(3):268-272. doi: 10.1016/j.eururo.2019.05.013. Epub 2019 May 23.

PMID:
31128968
22.

Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality.

Dess RT, Hartman HE, Mahal BA, Soni PD, Jackson WC, Cooperberg MR, Amling CL, Aronson WJ, Kane CJ, Terris MK, Zumsteg ZS, Butler S, Osborne JR, Morgan TM, Mehra R, Salami SS, Kishan AU, Wang C, Schaeffer EM, Roach M 3rd, Pisansky TM, Shipley WU, Freedland SJ, Sandler HM, Halabi S, Feng FY, Dignam JJ, Nguyen PL, Schipper MJ, Spratt DE.

JAMA Oncol. 2019 Jul 1;5(7):975-983. doi: 10.1001/jamaoncol.2019.0826.

23.

Association Between Twitter Reception at a National Urology Conference and Future Publication Status.

Nolte AC, Nguyen KA, Perecman A, Katz MS, Kenney PA, Cooperberg MR, Gross CP, Leapman MS.

Eur Urol Focus. 2019 May 15. pii: S2405-4569(19)30140-3. doi: 10.1016/j.euf.2019.05.004. [Epub ahead of print]

PMID:
31103604
24.

Influence of African American race on the association between preoperative biopsy grade group and adverse histopathologic features of radical prostatectomy.

Aminsharifi A, Schulman A, Howard LE, Tay KJ, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ, Polascik TJ.

Cancer. 2019 Sep 1;125(17):3025-3032. doi: 10.1002/cncr.32168. Epub 2019 May 1.

PMID:
31042315
25.

Validity of the National Death Index to ascertain the date and cause of death in men having undergone prostatectomy for prostate cancer.

Moghanaki D, Howard LE, De Hoedt A, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ.

Prostate Cancer Prostatic Dis. 2019 Dec;22(4):633-635. doi: 10.1038/s41391-019-0146-1. Epub 2019 Apr 29.

26.

Poorly controlled diabetes increases the risk of metastases and castration-resistant prostate cancer in men undergoing radical prostatectomy: Results from the SEARCH database.

Nik-Ahd F, Howard LE, Eisenberg AT, Aronson WJ, Terris MK, Cooperberg MR, Amling CL, Kane CJ, Freedland SJ.

Cancer. 2019 Aug 15;125(16):2861-2867. doi: 10.1002/cncr.32141. Epub 2019 Apr 29.

PMID:
31034601
27.

A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology for Men on Active Surveillance.

Kornberg Z, Cooperberg MR, Cowan JE, Chan JM, Shinohara K, Simko JP, Tenggara I, Carroll PR.

J Urol. 2019 Apr 26:101097JU0000000000000290. doi: 10.1097/JU.0000000000000290. [Epub ahead of print]

PMID:
31026214
28.

Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies.

Jackson WC, Silva J, Hartman HE, Dess RT, Kishan AU, Beeler WH, Gharzai LA, Jaworski EM, Mehra R, Hearn JWD, Morgan TM, Salami SS, Cooperberg MR, Mahal BA, Soni PD, Kaffenberger S, Nguyen PL, Desai N, Feng FY, Zumsteg ZS, Spratt DE.

Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):778-789. doi: 10.1016/j.ijrobp.2019.03.051. Epub 2019 Apr 6.

PMID:
30959121
29.

Stability of a 17-Gene Genomic Prostate Score in Serial Testing of Men on Active Surveillance of Early Stage Prostate Cancer.

Cedars BE, Washington SL 3rd, Cowan JE, Leapman M, Tenggara I, Chan JM, Cooperberg MR, Carroll PR.

J Urol. 2019 Apr 8:101097JU0000000000000271. doi: 10.1097/JU.0000000000000271. [Epub ahead of print]

PMID:
30958742
30.

Evaluating the Safety of Active Surveillance: Outcomes of Deferred Radical Prostatectomy after an Initial Period of Surveillance.

Balakrishnan AS, Cowan JE, Cooperberg MR, Shinohara K, Nguyen HG, Carroll PR.

J Urol. 2019 Sep;202(3):506-510. doi: 10.1097/JU.0000000000000247. Epub 2019 Aug 8.

PMID:
30958738
31.

High-throughput, Efficient, and Unbiased Capture of Small RNAs from Low-input Samples for Sequencing.

Belair CD, Hu T, Chu B, Freimer JW, Cooperberg MR, Blelloch RH.

Sci Rep. 2019 Feb 19;9(1):2262. doi: 10.1038/s41598-018-38458-7.

32.

First-year weight loss with androgen-deprivation therapy increases risks of prostate cancer progression and prostate cancer-specific mortality: results from SEARCH.

Griffin K, Csizmadi I, Howard LE, Pomann GM, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Beebe-Dimmer J, Freedland SJ.

Cancer Causes Control. 2019 Mar;30(3):259-269. doi: 10.1007/s10552-019-1133-5. Epub 2019 Jan 30.

PMID:
30701374
33.

Focal laser ablation as clinical treatment of prostate cancer: report from a Delphi consensus project.

van Luijtelaar A, Greenwood BM, Ahmed HU, Barqawi AB, Barret E, Bomers JGR, Brausi MA, Choyke PL, Cooperberg MR, Eggener S, Feller JF, Frauscher F, George AK, Hindley RG, Jenniskens SFM, Klotz L, Kovacs G, Lindner U, Loeb S, Margolis DJ, Marks LS, May S, Mcclure TD, Montironi R, Nour SG, Oto A, Polascik TJ, Rastinehad AR, De Reyke TM, Reijnen JS, de la Rosette JJMCH, Sedelaar JPM, Sperling DS, Walser EM, Ward JF, Villers A, Ghai S, Fütterer JJ.

World J Urol. 2019 Oct;37(10):2147-2153. doi: 10.1007/s00345-019-02636-7. Epub 2019 Jan 22.

34.

Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS).

Newcomb LF, Zheng Y, Faino AV, Bianchi-Frias D, Cooperberg MR, Brown MD, Brooks JD, Dash A, Fabrizio MD, Gleave ME, Liss M, Morgan TM, Thompson IM, Wagner AA, Carroll PR, Nelson PS, Lin DW.

Prostate Cancer Prostatic Dis. 2019 Sep;22(3):438-445. doi: 10.1038/s41391-018-0124-z. Epub 2019 Jan 21.

35.

Feasibility, Acceptability, and Behavioral Outcomes from a Technology-enhanced Behavioral Change Intervention (Prostate 8): A Pilot Randomized Controlled Trial in Men with Prostate Cancer.

Kenfield SA, Van Blarigan EL, Ameli N, Lavaki E, Cedars B, Paciorek AT, Monroy C, Tantum LK, Newton RU, Signorell C, Suh JH, Zhang L, Cooperberg MR, Carroll PR, Chan JM.

Eur Urol. 2019 Jun;75(6):950-958. doi: 10.1016/j.eururo.2018.12.040. Epub 2019 Jan 10.

PMID:
30638635
36.

ESTIMATING AND COMPARING CANCER PROGRESSION RISKS UNDER VARYING SURVEILLANCE PROTOCOLS.

Lange JM, Gulati R, Leonardson AS, Lin DW, Newcomb LF, Trock BJ, Carter HB, Cooperberg MR, Cowan JE, Klotz LH, Etzioni R.

Ann Appl Stat. 2018 Sep;12(3):1773-1795. doi: 10.1214/17-AOAS1130. Epub 2018 Sep 11.

37.

Socioeconomic status, race, and long-term outcomes after radical prostatectomy in an equal access health system: Results from the SEARCH database.

Everist MM, Howard LE, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ.

Urol Oncol. 2019 Apr;37(4):289.e11-289.e17. doi: 10.1016/j.urolonc.2018.12.004. Epub 2018 Dec 28.

PMID:
30598238
38.

Health Care Delivery for Metastatic Hormone-sensitive Prostate Cancer Across the Globe.

Herlemann A, Washington SL 3rd, Cooperberg MR.

Eur Urol Focus. 2019 Mar;5(2):155-158. doi: 10.1016/j.euf.2018.12.003. Epub 2018 Dec 23. Review.

PMID:
30587443
39.

Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer.

Behr SC, Aggarwal R, VanBrocklin HF, Flavell RR, Gao K, Small EJ, Blecha J, Jivan S, Hope TA, Simko JP, Kurhanewicz J, Noworolski SM, Korn NJ, De Los Santos R, Cooperberg MR, Carroll PR, Nguyen HG, Greene KL, Langton-Webster B, Berkman CE, Seo Y.

J Nucl Med. 2019 Jul;60(7):910-916. doi: 10.2967/jnumed.118.220715. Epub 2018 Nov 21.

PMID:
30464040
40.

Does race predict the development of metastases in men who receive androgen-deprivation therapy for a biochemical recurrence after radical prostatectomy?

Vidal AC, Howard LE, De Hoedt A, Kane CJ, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Lechpammer S, Flanders SC, Freedland SJ.

Cancer. 2019 Feb 1;125(3):434-441. doi: 10.1002/cncr.31808. Epub 2018 Nov 14.

PMID:
30427535
41.

Statins are Associated With Increased Biochemical Recurrence After Radical Prostatectomy in Diabetic Men but no Association was Seen in Men also Taking Metformin: Results From the SEARCH Database.

Aminsharifi A, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Polascik TJ, Freedland SJ.

Clin Genitourin Cancer. 2019 Feb;17(1):e140-e149. doi: 10.1016/j.clgc.2018.09.020. Epub 2018 Oct 4.

PMID:
30366879
42.

Obesity, risk of biochemical recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database.

Freedland SJ, Branche BL, Howard LE, Hamilton RJ, Aronson WJ, Terris MK, Cooperberg MR, Amling CL, Kane CJ; SEARCH Database Study Group.

BJU Int. 2019 Jul;124(1):69-75. doi: 10.1111/bju.14594. Epub 2018 Nov 16.

PMID:
30347135
43.

The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target.

Zhao SG, Lehrer J, Chang SL, Das R, Erho N, Liu Y, Sjöström M, Den RB, Freedland SJ, Klein EA, Karnes RJ, Schaeffer EM, Xu M, Speers C, Nguyen PL, Ross AE, Chan JM, Cooperberg MR, Carroll PR, Davicioni E, Fong L, Spratt DE, Feng FY.

J Natl Cancer Inst. 2019 Mar 1;111(3):301-310. doi: 10.1093/jnci/djy141.

PMID:
30321406
44.

Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer.

Whitney CA, Howard LE, Freedland SJ, DeHoedt AM, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Daskivich TJ.

Prostate Cancer Prostatic Dis. 2019 May;22(2):252-260. doi: 10.1038/s41391-018-0095-0. Epub 2018 Oct 2.

PMID:
30279582
45.

Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital.

Patel DN, Jha S, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Chapin BF, Freedland SJ.

Int J Urol. 2018 Dec;25(12):998-1004. doi: 10.1111/iju.13806. Epub 2018 Sep 25.

PMID:
30253446
46.

Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.

Leapman MS, Nguyen HG, Cowan JE, Xue L, Stohr B, Simko J, Cooperberg MR, Carroll PR.

Eur Urol. 2018 Nov;74(5):668-675. doi: 10.1016/j.eururo.2018.08.020. Epub 2018 Sep 1.

PMID:
30181067
47.

Genomic Prostate Score, PI-RADS™ version 2 and Progression in Men with Prostate Cancer on Active Surveillance.

Kornberg Z, Cowan JE, Westphalen AC, Cooperberg MR, Chan JM, Zhao S, Shinohara K, Carroll PR.

J Urol. 2019 Feb;201(2):300-307. doi: 10.1016/j.juro.2018.08.047.

PMID:
30179620
48.

Contemporary prostate cancer radiation therapy in the United States: Patterns of care and compliance with quality measures.

Lee DJ, Barocas DA, Zhao Z, Huang LC, Koyama T, Resnick MJ, Conwill R, McCollum D, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hashibe M, Kaplan SH, Paddock LE, Stroup AM, Wu XC, Penson DF, Hoffman KE.

Pract Radiat Oncol. 2018 Sep - Oct;8(5):307-316. doi: 10.1016/j.prro.2018.04.009.

PMID:
30177030
49.

Practice patterns of primary EBRT with and without ADT in prostate cancer treatment.

Schmidt B, Eapen RS, Cowan JE, Broering JM, Greene KL, Carroll PR, Cooperberg MR.

Prostate Cancer Prostatic Dis. 2019 Mar;22(1):117-124. doi: 10.1038/s41391-018-0084-3. Epub 2018 Aug 31.

PMID:
30171230
50.

Prostate Cancer Markers.

Gadzinski AJ, Cooperberg MR.

Cancer Treat Res. 2018;175:55-86. doi: 10.1007/978-3-319-93339-9_3.

PMID:
30168117

Supplemental Content

Loading ...
Support Center